Stryker Corporation $SYK Shares Sold by Xponance Inc.

Xponance Inc. cut its stake in Stryker Corporation (NYSE:SYK) by 3.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 59,926 shares of the medical technology company’s stock after selling 2,103 shares during the quarter. Xponance Inc.’s holdings in Stryker were worth $22,153,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of SYK. Brighton Jones LLC raised its holdings in Stryker by 15.4% in the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after acquiring an additional 609 shares during the last quarter. Schnieders Capital Management LLC. acquired a new position in shares of Stryker during the 2nd quarter valued at about $205,000. Daymark Wealth Partners LLC grew its holdings in shares of Stryker by 7.4% in the second quarter. Daymark Wealth Partners LLC now owns 7,306 shares of the medical technology company’s stock valued at $2,890,000 after purchasing an additional 501 shares during the period. Arkadios Wealth Advisors increased its position in Stryker by 17.2% during the second quarter. Arkadios Wealth Advisors now owns 4,747 shares of the medical technology company’s stock worth $1,878,000 after purchasing an additional 695 shares during the last quarter. Finally, Premier Path Wealth Partners LLC raised its stake in Stryker by 4.4% during the second quarter. Premier Path Wealth Partners LLC now owns 1,746 shares of the medical technology company’s stock worth $691,000 after purchasing an additional 73 shares during the period. 77.09% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director Ronda E. Stryker sold 250,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the sale, the director directly owned 2,457,331 shares of the company’s stock, valued at approximately $891,814,566.52. This represents a 9.23% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 5.90% of the stock is currently owned by corporate insiders.

Stryker Stock Performance

SYK opened at $386.04 on Friday. Stryker Corporation has a 1-year low of $329.16 and a 1-year high of $404.87. The stock has a market cap of $147.73 billion, a P/E ratio of 45.96, a P/E/G ratio of 2.24 and a beta of 0.87. The stock’s 50 day simple moving average is $362.53 and its 200 day simple moving average is $369.14. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.89 and a quick ratio of 1.21.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, January 29th. The medical technology company reported $4.47 EPS for the quarter, topping analysts’ consensus estimates of $4.40 by $0.07. The firm had revenue of $7.17 billion during the quarter, compared to analysts’ expectations of $7.12 billion. Stryker had a return on equity of 24.41% and a net margin of 12.92%.The firm’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same quarter last year, the business posted $4.01 EPS. As a group, equities analysts anticipate that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.9%. Stryker’s dividend payout ratio (DPR) is presently 41.90%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on SYK shares. The Goldman Sachs Group set a $399.00 price objective on Stryker in a research note on Friday, January 9th. Robert W. Baird set a $437.00 price target on shares of Stryker in a research note on Friday, January 30th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Stryker in a research note on Monday, December 22nd. Piper Sandler reissued an “overweight” rating on shares of Stryker in a research note on Tuesday, January 27th. Finally, Citizens Jmp raised Stryker from a “market perform” rating to an “outperform” rating and set a $440.00 price target on the stock in a research report on Friday, December 19th. Thirteen investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $426.47.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.